IRIS
SAVARINO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 42.772
Totale 42.772
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 42.772
Totale 42.772
Salva come PNG Salva come JPEG
Città #
Genova 33.728
Rapallo 4.096
Genoa 3.121
Vado Ligure 1.765
Bordighera 62
Totale 42.772
Salva come PNG Salva come JPEG
Nome #
Hepatobiliary and Pancreatic: A rare cause of portal hypertension. 173
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 164
Time pattern of gastric acidity in Barrett's esophagus 158
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 154
Vigor of peristalsis during multiple rapid swallows is inversely correlated with acid exposure time in patients with NERD 151
Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD) 150
13C-mixed triglyceride (13C-MTG) breath-test (BT) in Cystic Fibrosis (CF). 149
Positive PET in a patient with esophageal leiomyoma. 148
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. 147
Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. 147
Alginate controls heartburn in patients with erosive and nonerosive reflux disease. 147
A pharmacodynamic study of two omeprazole regimens suitable for long-term treatment of duodenal ulcer. 145
Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis 144
Circadian monitoring of gastric juice mutagenicity. 141
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 141
Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. 141
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 141
Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group 140
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 140
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. 140
Burden of illness in Italian patients with gastro-oesophageal reflux disease. 138
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 138
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 138
Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn 138
Barrett's esophagus in 2016: From pathophysiology to treatment 138
Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure. 137
Ilaprazole for the treatment of gastro-esophageal reflux 135
Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. 135
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. 134
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure 133
Proton pump inhibitors: use and misuse in the clinical setting 133
Measurement of oro-caecal transit time by magnetic resonance imaging. 132
Can artificial neural networks be beneficial in diagnosing gastro-oesophageal reflux disease? 132
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. 131
New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. 131
A comparison of the effects on intragastric acidity of bedtime or dinnertime administration of a once daily dose of famotidine. 131
24-hour study of intragastric acidity in duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry. 131
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 131
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 131
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study 130
Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. 129
Breath tests to assess alcoholic liver disease. 129
A safety review of proton pump inhibitors to treat acid-related digestive diseases 129
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 128
Antimony and glass pH electrodes can be used interchangeably in 24-hour studies of gastric acidity. 128
OAM for cure of Helicobacter pylori infection. 128
NERD: an umbrella term including heterogeneous subpopulations. 128
A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. 128
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 128
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 127
Once and twice daily doses of H2 antagonists revisited, using continuous intragastric pH monitoring. 127
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 127
External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis 126
Circadian reduction of chromium in the gastric environment. 126
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 126
Blessed are those who have not seen and yet have believed 125
Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. 125
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 125
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs pantoprazole. 124
Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. 124
Nevoid Basal Cell Carcinoma Syndrome in infants: improving diagnosis. 124
An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. 124
Are duodenal ulcer seasonal fluctuations paralleled by seasonal changes in 24-hour gastric acidity and Helicobacter pylori infection? 124
Acid and gastric metaplasia in the duodenum 123
Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole. 123
Are proton pump inhibitors really so dangerous? 123
24-H comparison between pH values of continuous intraluminal recording and simultaneous gastric aspiration. 123
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. 122
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 122
A comparison of five maintenance therapies for reflux esophagitis 122
Esophageal acid exposure still plays a major role in patients with NERD. 122
Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori 121
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 121
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 121
Drugs for improving esophageal mucosa defense: Where are we now and where are we going? 121
Discriminant value of dyspepsia subgroups. 120
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 120
Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. 120
Processing gastric pH measurements. 119
A Comparison Between Lactose Breath Test and Quick Test on Duodenal Biopsies for Diagnosing Lactase Deficiency in Patients With Self-reported Lactose Intolerance. 119
Helicobacter pylori and acid secretion. 119
Feasibility of the cut-and-push method for removing large caliber, soft, percutaneous endoscopic gastrostomy devices. 119
An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease 118
Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. 118
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 118
24-hour gastric pH and extent of duodenal gastric metaplasia in Helicobacter pylori-positive patients. 118
Helicobacter pylori and tolerance to H2-blockers. 118
Influence of time of dinner on nocturnal gastric pH. 118
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 118
Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer. 118
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. 118
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 118
The relevance of weakly acidic reflux in patients with Barrett's esophagus. 118
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 118
Neural networks analysis of 13C excretion data simplifies the 13C-octanoic ac. breath test for gastric emptying evaluation 117
Lansoprazole vs omeprazole for gastro.oesophageal reflux disease: a pH-metric comparison. 117
Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors 117
Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. 117
Starry Liver: An Unexpected Diagnosis 117
The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up 117
Totale 12.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.128
article - articoli 111.777
book - libri 365
conference - conferenze 1.672
curatela - curatele 0
other - altro 6.124
patent - brevetti 0
selected - selezionate 0
volume - volumi 190
Totale 240.256
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209.948 0 0 0 0 1.113 1.260 1.858 845 1.089 2.088 1.197 498
2020/20213.251 186 362 295 333 174 294 123 332 317 354 224 257
2021/20225.241 161 297 378 744 235 408 388 1.125 212 497 177 619
2022/20234.913 530 265 60 424 947 890 6 379 886 32 437 57
2023/20242.198 117 313 50 222 183 394 127 99 138 38 140 377
2024/20251.973 272 595 262 449 395 0 0 0 0 0 0 0
Totale 43.339